YESTAR HEALTH (02393.HK): Interim Revenue Down 17.6% to RMB 662 Million, Swing to Loss
- The medical segment's gross profit margin rose 5.8 percentage points to about 22.7% after cooperation with low-margin customers ended, while the non-medical segment's gross profit margin rose 4.3 percentage points to 18.5% as the full increase in industrial film costs was passed on to customers.
- An impairment loss reversal on financial assets of RMB 7.7 million was recognised; interest-bearing loans carried rates of 1.95% to 4.80%; and the Group had 400 employees, against 479 a year earlier.
- The Group was in a net cash position; as at 31 December 2025, cash and cash equivalents were approximately RMB 234.4 million, current borrowings approximately RMB 160.9 million and the current ratio approximately 1.37.
NewTimeSpace (newtimespace.com) News: On 16 September 2026, Yestar Healthcare Holdings Company Limited (stock code: 02393) published its 2026 interim report. For the six months ended 30 June 2026, revenue fell about 17.6% year on year to RMB 661.6 million while gross profit rose about 8.3% to RMB 144.8 million. The Group recorded a loss of RMB 479,000, against a profit of RMB 11.1 million a year earlier, with a loss attributable to owners of the Company of RMB 3.2 million and basic loss per share of RMB 0.14 cents. The Board resolved not to declare an interim dividend.
By segment, the medical business recorded revenue of RMB 531.7 million, or 80.4% of total revenue, down about 26.4% year on year, while the non-medical business recorded revenue of RMB 129.9 million, or 19.6% of total revenue, up about 61.3%. The decline in revenue was mainly due to the impact of China's centralised procurement policy on the medical segment. On expenses, administrative expenses fell about 3.0% to RMB 75.4 million and finance costs fell about 34.2% to RMB 4.3 million, while other expenses rose about 27.7% to RMB 22.4 million.
On financial position, as at 30 June 2026, the Group had cash and cash equivalents of approximately RMB 194.4 million, current bank and other borrowings of approximately RMB 154.0 million and a current ratio of approximately 1.35, and no gearing ratio was presented as the Group was in a net cash position. On business developments, the Group entered into an agreement on 6 February 2026 to acquire various high-performance materials equipment for a total consideration of USD 5,350,000. Development of the Group's own-brand "Yes!Star" S2 film camera has completed functional and performance verification and testing, and production introduction is under way.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HENGRUI PHARMA (01276.HK): HRS-4139 Tablets Cleared for Clinical Trial in Moderate-to-Severe Plaque Psoriasis
- HENGRUI PHARMA (01276.HK): Recaticimab Cleared for Clinical Trials, Phase III Study Planned in Stroke Recurrence
- SBP GROUP (01177.HK): NDA for TQH2722 "IL-4Rα Antibody" Accepted for Review
- SBP GROUP (01177.HK): NDA for TQB2102 "HER2 Bispecific ADC" Accepted for Review
- YUK WING GP (01536.HK): Controlling Shareholder Sells 38.54% Stake, Hellobaby Becomes Substantial Shareholder
